PCD (Multiple myeloma and other plasma cell dyscrasias)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\PCD (Multiple myeloma and other plasma cell dyscrasias).php on line 2
PCD (Multiple myeloma and other plasma cell dyscrasias)

LE WE PMID CA

PCD (Multiple myeloma and other plasma cell dyscrasias)

1859

PCD (Multiples Myelom und andere Plasmazelldyskrasien)

Amyloidosis

Angiogenesis

Antibodies (Immunochemistry)

Bone (Physiology)

Bortezomib ttProteasom

Carfilzomib ttProteasom

Centrosome

Chronic inflammatory demyelinizing polyneuropathy

Dickkopf1

Dysimmune neuropathies

Gaucher s disease

Genetic instability

Histone deacetylase

KLF9

Lenalidomide

Multifocal motor neuropathy

Myelofibrosis

Noxa

Osteoblasts

Osteoclasts

Osteoporosis

Panobinostat LBH589 ttHDAC

PCD (MGUS)

PCD (Multiple myeloma and other plasma cell dyscrasias)

Phosphate (Hypophosphatemia)

Pomalidomide

Proteomics

Spleen (Ectomy)

Thalidomide

Thrombophilia

Thrombosis (Prophylaxis)

Vaccine (Oncology)

2007 1	Multiple myeloma: causes and consequences of delay in diagnosis. [17846059] QJM 100(10): 635-40 (2007)
1997 2	The development of cast nephropathy in multiple myeloma. [9474345] QJM 90(11): 653-6 (1997)
2008 3	Multiple myeloma: epidemiology and therapeutic options. [19093334] Manag Care 17(7 Suppl 6): 9-15 (2008)
2010 4	New developments in the treatment of patients with multiple myeloma. [20103818] Neth J Med 68(1): 24-32 (2010)
2008 5	Current and emerging treatments for multiple myeloma. [18774881] J Manag Care Pharm 14(7 Suppl): 12-9 (2008)
2008 6	A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. [18728702] Ther Clin Risk Manag 4(1): 129-36 (2008)
2007 7	Review of thalidomide in the treatment of newly diagnosed multiple myeloma. [18472975] Ther Clin Risk Manag 3(4): 543-52 (2007)
2009 8	Bortezomib for the treatment of multiple myeloma patients. [19567211] Health Technol Assess 13 Suppl 1(-): 29-33 (2009)
2010 9	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. [20694078] Core Evid 4(-): 215-45 (2010)
2003 10	Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. [12707095] Arch Dermatol 139(4): 475-86 (2003)
2004 11	Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias. [15155772] J Leukoc Biol 76(3): 528-36 (2004)
2007 12	Multiple myeloma/hypercalcemia. [17634143] Arthritis Res Ther 9 Suppl 1(-): S4 (2007)
2006 13	Light-chain (AL) amyloidosis: diagnosis and treatment. [17699366] Clin J Am Soc Nephrol 1(6): 1331-41 (2006)
1966 14	Orthopaedic aspects of myelomatosis. [5333449] J Bone Joint Surg Br 48(4): 703-28 (1966)
2009 15	Targeted therapies in multiple myeloma. [19343299] Target Oncol 4(1): 23-36 (2009)
2008 16	The role of novel drugs in multiple myeloma. [18790953] Ann Oncol 19 Suppl 7(-): vii121-7 (2008)
2008 17	Maintenance treatment in multiple myeloma. [18519405] Ann Oncol 19 Suppl 4(-): iv54-5 (2008)
2008 18	Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. [18456769] Ann Oncol 19 Suppl 2(-): ii55-7 (2008)
2007 19	Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. [17631598] Ann Oncol 18 Suppl 9(-): ix64-70 (2007)
2006 20	Hematological malignancies: myeloma. [17018714] Ann Oncol 17 Suppl 10(-): x137-43 (2006)
2005 21	Myeloma bone disease: pathophysiology and management. [15928069] Ann Oncol 16(8): 1223-31 (2005)
2005 22	Advances in biology and treatment of multiple myeloma. [15958439] Ann Oncol 16 Suppl 2(-): ii106-12 (2005)
2000 23	Molecular aspects of multiple myeloma. [11106109] Ann Oncol 11(10): 1217-28 (2000)
2006 24	Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. [16598756] Cancer 106(10): 2171-80 (2006)
2003 25	A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. [12733143] Cancer 97(10): 2440-52 (2003)
1997 26	Mechanisms of bone lesions in multiple myeloma and lymphoma. [9362422] Cancer 80(8 Suppl): 1557-63 (1997)
2003 27	Thalidomide and its derivatives: new promise for multiple myeloma. [14581892] Cancer Control 10(5): 375-83 (2003)
2003 28	Trials of arsenic trioxide in multiple myeloma. [14581891] Cancer Control 10(5): 370-4 (2003)
2003 29	Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. [14581890] Cancer Control 10(5): 361-9 (2003)
2003 30	Multiple myeloma: increasing our treatment options. [14581889] Cancer Control 10(5): 357-8 (2003)
2001 31	NCCN: Multiple myeloma. [11760563] Cancer Control 8(6 Suppl 2): 78-87 (2001)
2009 32	Myeloma bone disease: recent advances in biology, diagnosis, and treatment. [19286761] Oncologist 14(3): 276-83 (2009)
2009 33	Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? [19286760] Oncologist 14(3): 264-75 (2009)
2007 34	New drugs for myeloma. [17602058] Oncologist 12(6): 664-89 (2007)
2010 35	State-of-the-Art Management of Complications of Myeloma and Its Treatment. [20671999] Adv Hematol 2010(-): 343089 (2010)
2010 36	Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. [20095057] Am J Hematol 85(2): 95-6 (2010)
2006 37	Splenectomy in plasma cell dyscrasias: a review of the clinical practice. [16937390] Am J Hematol 81(12): 946-54 (2006)
2008 38	Thalidomide for treatment of multiple myeloma: 10 years later. [18245666] Blood 111(8): 3968-77 (2008)
2008 39	Multiple myeloma. [18332230] Blood 111(6): 2962-72 (2008)
2007 40	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. [17634408] Blood 110(9): 3112-21 (2007)
2006 41	Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. [16917004] Blood 108(13): 3992-6 (2006)
2004 42	Advances in biology of multiple myeloma: clinical applications. [15090448] Blood 104(3): 607-18 (2004)
2004 43	Treatment of multiple myeloma. [12969978] Blood 103(1): 20-32 (2004)
2004 44	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). [15194540] Haematologica 89(6): 717-41 (2004)
1999 45	Treatment of multiple myeloma. [10091392] Haematologica 84(1): 36-58 (1999)
2009 46	Novel therapies for relapsed myeloma. [20008242] Hematology Am Soc Hematol Educ Program -(-): 578-86 (2009)
2009 47	How to treat a newly diagnosed young patient with multiple myeloma. [20008240] Hematology Am Soc Hematol Educ Program -(-): 555-65 (2009)
2007 48	The treatment of relapsed and refractory multiple myeloma. [18024646] Hematology Am Soc Hematol Educ Program -(-): 317-23 (2007)
2007 49	Strategies for risk-adapted therapy in myeloma. [18024644] Hematology Am Soc Hematol Educ Program -(-): 304-10 (2007)
2004 50	Multiple myeloma. [15561686] Hematology Am Soc Hematol Educ Program -(-): 237-56 (2004)
2003 51	Advances in biology and therapy of multiple myeloma. [14633785] Hematology Am Soc Hematol Educ Program -(-): 248-78 (2003)
2002 52	Multiple myeloma. [12446425] Hematology Am Soc Hematol Educ Program -(-): 214-40 (2002)
2001 53	Multiple myeloma. [11722983] Hematology Am Soc Hematol Educ Program -(-): 157-77 (2001)
2006 54	Multiple myeloma. [16885408] J Am Soc Nephrol 17(9): 2533-45 (2006)
2002 55	Molecular aspects of multiple myeloma. [12354927] Mol Pathol 55(5): 273-83 (2002)
2006 56	Myeloma--new approaches to combined nephrological-haematological management. [16396976] Nephrol Dial Transplant 21(3): 582-90 (2006)
1995 57	Acute myeloma kidney. [8569099] Kidney Int 48(4): 1347-61 (1995)
2006 58	Use of 99mTc-sestamibi scintigraphy in multiple myeloma. [16513630] J Nucl Med 47(3): 555 (2006)
2004 59	Multiple myeloma: clinical review and diagnostic imaging. [14990813] Radiology 231(1): 11-23 (2004)
2010 60	Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. [20851941] Radiology 257(1): 195-204 (2010)
2011 61	A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? [21778706] Acta Haematol 126(3): 163-8 (2011)
2009 62	Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. [19763570] Ann Hematol 88(12): 1161-8 (2009)
2010 63	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [20555068] Ann Oncol 21 Suppl 5(-): v155-7 (2010)
2010 64	Multiple myeloma. [20943635] Ann Oncol 21 Suppl 7(-): vii313-9 (2010)
2010 65	Multiple myeloma. [20943607] Ann Oncol 21 Suppl 7(-): vii143-50 (2010)
2009 66	Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454476] Ann Oncol 20 Suppl 4(-): 97-9 (2009)
2009 67	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. [19465418] Ann Oncol 20(8): 1303-17 (2009)
2010 68	Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. [20966307] AJR Am J Roentgenol 195(5): 1057-65 (2010)
2009 69	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. [19955246] Mayo Clin Proc 84(12): 1095-110 (2009)
2003 70	Review of 1027 patients with newly diagnosed multiple myeloma. [12528874] Mayo Clin Proc 78(1): 21-33 (2003)
2007 71	Myeloma bone disease and proteasome inhibition therapies. [17494860] Blood 110(4): 1098-104 (2007)
2011 72	Can multiple myeloma become a curable disease? [21880640] Haematologica 96(9): 1246-8 (2011)
2010 73	Novel drugs for the treatment of multiple myeloma. [20442442] Haematologica 95(5): 702-4 (2010)
2003 74	Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients. [12935985] Haematologica 88(8): 958-60 (2003)
2003 75	Bone marrow angiogenesis in multiple myeloma: closing in on the loop. [12604399] Haematologica 88(2): 122-4 (2003)
2007 76	Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. [18024376] Haematologica 92(10): 1399-406 (2007)
2006 77	Thrombotic complications of myeloma therapy. [17124082] Hematology Am Soc Hematol Educ Program -(-): 348-55 (2006)
2006 78	Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. [17124081] Hematology Am Soc Hematol Educ Program -(-): 338-47 (2006)
2010 79	Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. [21239811] Hematology Am Soc Hematol Educ Program 2010(-): 310-3 (2010)
2005 80	Managing myeloma kidney. [16330796] Ann Intern Med 143(11): 835-7 (2005)
2002 81	The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. [11955031] Ann Intern Med 136(8): 619-29 (2002)
1976 82	Waldenström's macroglobulinemia: review of 45 cases. [817791] Can Med Assoc J 114(10): 899-900, 902, 905 (1976)
1976 83	M components-a review of 1242 cases. [817789] Can Med Assoc J 114(10): 889-92, 895 (1976)
1957 84	Multiple myelomatosis: a review based on 68 patients. [13426890] Can Med Assoc J 76(8): 605-15 (1957)
2005 85	Light- and heavy-chain deposition disease (LHCDD): difficulty in diagnosis and treatment. [16258202] Intern Med 44(9): 915-6 (2005)
2003 86	Bone marrow immunohistology of plasma cell neoplasms. [12783964] J Clin Pathol 56(6): 406-11 (2003)
2006 87	Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. [16706268] Mayo Clin Proc 81(5): 693-703 (2006)
2005 88	Multiple myeloma: diagnosis and treatment. [16212152] Mayo Clin Proc 80(10): 1371-82 (2005)
2002 89	Current therapy for multiple myeloma. [12173715] Mayo Clin Proc 77(8): 813-22 (2002)
1994 90	Multiple myeloma: current treatment. [7518081] Postgrad Med J 70(824): 404-10 (1994)
1959 91	Clinical features of multiple myeloma. A review of the clinical manifestations and laboratory investigations in 40 cases. [13813930] Postgrad Med J 35(-): 662-7 (1959)
1948 92	Multiple myelomatosis; a clinico-pathological review, with a report of a case of myeloblastic type. [18857415] Postgrad Med J 24(271): 269-82 (1948)
1974 93	Glomerular lesions in dysproteinemias. [4136753] Kidney Int 5(4): 249-52 (1974)
2008 94	Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. [18274746] Ann Hematol 87(6): 439-49 (2008)
2007 95	Flow cytometric immunophenotyping of plasmacytic neoplasms. [17210527] Am J Clin Pathol 127(2): 172-4 (2007)
2010 96	Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. [20713974] Mayo Clin Proc 85(10): 933-42 (2010)
2010 97	Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. [20884827] Mayo Clin Proc 85(10): 945-8 (2010)
2004 98	On the "significance" of monoclonal gammopathy of undetermined significance. [15244379] Mayo Clin Proc 79(7): 855-6 (2004)
2011 99	Immunoglobulin free light chain dimers in human diseases. [21442150] ScientificWorldJournal 11(-): 726-35 (2011)
2010 100	Kidney disease associated with plasma cell dyscrasias. [20462963] Blood 116(9): 1397-404 (2010)
2010 101	Dealing with neuropathy in plasma-cell dyscrasias. [21239830] Hematology Am Soc Hematol Educ Program 2010(-): 423-30 (2010)
2007 102	Bleeding and thrombosis risks in plasma cell dyscrasias. [18024624] Hematology Am Soc Hematol Educ Program -(-): 158-64 (2007)
2006 103	A practical update on the use of bortezomib in the management of multiple myeloma. [16401713] Oncologist 11(1): 51-61 (2006)
2010 104	Current multiple myeloma treatment strategies with novel agents: a European perspective. [20086168] Oncologist 15(1): 6-25 (2010)
2007 105	Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. [17766658] Oncologist 12(8): 978-90 (2007)
2003 106	Practical considerations for the measurement of free light chains in serum. [12881439] Clin Chem 49(8): 1252-7 (2003)
2008 107	Screening algorithms for monoclonal gammopathies. [18957556] Clin Chem 54(11): 1753-5 (2008)
2009 108	Heavy/Light-chain analysis of monoclonal gammopathies. [19589841] Clin Chem 55(9): 1606-8 (2009)
2007 109	Management of paraproteinaemia. [17403946] Postgrad Med J 83(978): 217-23 (2007)
2007 110	Current status and future directions in the treatment of multiple myeloma. [17935663] Chin Med J (Engl) 120(19): 1651-4 (2007)
2005 111	Targeted therapy in multiple myeloma. [15855892] Cancer Control 12(2): 91-104 (2005)
2009 112	Molecularly targeted therapies for dysimmune neuropathies. [19593413] Mol Med 15(7-8): 283-7 (2009)
2010 113	Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. [20465501] Expert Rev Mol Diagn 10(4): 465-80 (2010)
2012 114	KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. [22144178] Blood 119(6): 1450-8 (2012)
2007 115	Hypophosphatemia associated with paraproteinemia: a case report and review of the literature. [18237074] WMJ 106(8): 490-3 (2007)
2008 116	Newer therapeutic molecules for multiple myeloma. [19112201] Indian J Cancer 45(4): 142-8 (2008)
2010 117	Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. [20026810] J Clin Oncol 28(4): 690-7 (2010)
2010 118	Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. [20374647] J Hematol Oncol 3(-): 13 (2010)
2010 119	The evolution of melanoma diagnosis: 25 years beyond the ABCDs. [20671054] CA Cancer J Clin 60(5): 301-16 (2010)
2007 120	Multiple myeloma: charging toward a bright future. [17855486] CA Cancer J Clin 57(5): 301-18 (2007)
2009 121	Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. [19389500] Semin Hematol 46(2): 166-75 (2009)
2010 122	Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. [20473362] Expert Rev Hematol 3(2): 165-74 (2010)
2009 123	Communications on multiple myeloma. [21083446] Expert Rev Hematol 2(2): 129-31 (2009)
2009 124	Bortezomib in the management of multiple myeloma. [21188129] Cancer Manag Res 1(-): 107-17 (2009)
2003 125	The spectrum of plasma cell neoplasia in oral pathology. [12937388] Med Oral 8(4): 269-80 (2003)
2011 126	Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. [21654882] Core Evid 6(-): 43-57 (2011)
2008 127	The pathogenesis of the bone disease of multiple myeloma. [18406675] Bone 42(6): 1007-13 (2008)
2009 128	International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. [19798094] Leukemia 23(12): 2210-21 (2009)
2009 129	Novel immunotherapies. [20010170] Cancer J 15(6): 502-10 (2009)
2009 130	Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. [20010166] Cancer J 15(6): 473-8 (2009)
2011 131	Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide. [21501555] J Pharm Pharm Sci 14(1): 78-89 (2011)
2009 132	Stem cell transplantation for multiple myeloma. [19532019] Curr Opin Oncol 21(2): 162-70 (2009)
2007 133	Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. [17723971] Clin J Oncol Nurs 11(4): 569-74 (2007)
2007 134	New therapies in multiple myeloma. [17972050] Clin Exp Med 7(3): 83-97 (2007)
2009 135	Multiple myeloma. [19254626] Curr Probl Cancer 33(1): 7-64 (2009)
2004 136	Apoptosis of multiple myeloma. [15540896] Int J Hematol 80(3): 224-31 (2004)
2010 137	Mechanism of action of immunomodulatory agents in multiple myeloma. [20405248] Med Oncol 27 Suppl 1(-): S7-13 (2010)
2011 138	Multiple myeloma: a review of imaging features and radiological techniques. [22046568] Bone Marrow Res 2011(-): 583439 (2011)
2009 139	Serum-free light chain analysis: works in progress. [19728842] Clin Chem Lab Med 47(9): 1021-2 (2009)
2009 140	Centrosomes and myeloma; aneuploidy and proliferation. [19739237] Environ Mol Mutagen 50(8): 697-707 (2009)
2009 141	Monoclonal gammopathies--clinical and laboratory issues. [19841689] Clin Biochem Rev 30(3): 89-91 (2009)
2009 142	Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. [19841691] Clin Biochem Rev 30(3): 93-103 (2009)
2009 143	Screening panels for monoclonal gammopathies: time to change. [19841692] Clin Biochem Rev 30(3): 105-11 (2009)
2010 144	The DAC system and associations with multiple myeloma. [21120582] Invest New Drugs 28 Suppl 1(): S28-35 (2010)
2011 145	Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. [21114539] Eur J Haematol 86(2): 93-110 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\PCD (Multiple myeloma and other plasma cell dyscrasias).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\PCD (Multiple myeloma and other plasma cell dyscrasias).php on line 92